Abstract
The decision on which patients with muscle-invasive bladder cancer to consider for bladder preservation remains controversial. New promising technologies and biomarkers may allow to precise selection of patients for bladder preservation in the future. Currently, bladder preservation should only be considered in highly selected cases and in the setting of clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
